Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global PD-L1 Biomarker Testing Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Cancer Type (NSCLC, Kidney Cancer, Melanoma, Head and Neck, Bladder Cancer, Others)
4.2.2. By Assay Kit Type (PD-L1 22C3 IHC, PD-L1 28-8 IHC, PD-L1 SP263, PD-L1 SP142)
4.2.3. By End Use (Research and Development, Diagnostics)
4.2.4. By Company (2022)
4.3. Market Map
4.3.1. By Cancer Type
4.3.2. By Assay Kit Type
4.3.3. By End Use
4.3.4. By Region
5. Asia Pacific PD-L1 Biomarker Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Cancer Type
5.2.2. By Assay Kit Type
5.2.3. By End Use
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China PD-L1 Biomarker Testing Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Cancer Type
5.3.1.2.2. By Assay Kit Type
5.3.1.2.3. By End Use
5.3.2. India PD-L1 Biomarker Testing Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Cancer Type
5.3.2.2.2. By Assay Kit Type
5.3.2.2.3. By End Use
5.3.3. Australia PD-L1 Biomarker Testing Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Cancer Type
5.3.3.2.2. By Assay Kit Type
5.3.3.2.3. By End Use
5.3.4. Japan PD-L1 Biomarker Testing Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Cancer Type
5.3.4.2.2. By Assay Kit Type
5.3.4.2.3. By End Use
5.3.5. South Korea PD-L1 Biomarker Testing Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Cancer Type
5.3.5.2.2. By Assay Kit Type
5.3.5.2.3. By End Use
6. Europe PD-L1 Biomarker Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Cancer Type
6.2.2. By Assay Kit Type
6.2.3. By End Use
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France PD-L1 Biomarker Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Cancer Type
6.3.1.2.2. By Assay Kit Type
6.3.1.2.3. By End Use
6.3.2. Germany PD-L1 Biomarker Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Cancer Type
6.3.2.2.2. By Assay Kit Type
6.3.2.2.3. By End Use
6.3.3. Spain PD-L1 Biomarker Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Cancer Type
6.3.3.2.2. By Assay Kit Type
6.3.3.2.3. By End Use
6.3.4. Italy PD-L1 Biomarker Testing Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Cancer Type
6.3.4.2.2. By Assay Kit Type
6.3.4.2.3. By End Use
6.3.5. United Kingdom PD-L1 Biomarker Testing Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Cancer Type
6.3.5.2.2. By Assay Kit Type
6.3.5.2.3. By End Use
7. North America PD-L1 Biomarker Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Cancer Type
7.2.2. By Assay Kit Type
7.2.3. By End Use
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States PD-L1 Biomarker Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Cancer Type
7.3.1.2.2. By Assay Kit Type
7.3.1.2.3. By End Use
7.3.2. Mexico PD-L1 Biomarker Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Cancer Type
7.3.2.2.2. By Assay Kit Type
7.3.2.2.3. By End Use
7.3.3. Canada PD-L1 Biomarker Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Cancer Type
7.3.3.2.2. By Assay Kit Type
7.3.3.2.3. By End Use
8. South America PD-L1 Biomarker Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Cancer Type
8.2.2. By Assay Kit Type
8.2.3. By End Use
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil PD-L1 Biomarker Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Cancer Type
8.3.1.2.2. By Assay Kit Type
8.3.1.2.3. By End Use
8.3.2. Argentina PD-L1 Biomarker Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Cancer Type
8.3.2.2.2. By Assay Kit Type
8.3.2.2.3. By End Use
8.3.3. Colombia PD-L1 Biomarker Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Cancer Type
8.3.3.2.2. By Assay Kit Type
8.3.3.2.3. By End Use
9. Middle East and Africa PD-L1 Biomarker Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Cancer Type
9.2.2. By Assay Kit Type
9.2.3. By End Use
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa PD-L1 Biomarker Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Cancer Type
9.3.1.2.2. By Assay Kit Type
9.3.1.2.3. By End Use
9.3.2. Saudi Arabia PD-L1 Biomarker Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Cancer Type
9.3.2.2.2. By Assay Kit Type
9.3.2.2.3. By End Use
9.3.3. UAE PD-L1 Biomarker Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Cancer Type
9.3.3.2.2. By Assay Kit Type
9.3.3.2.3. By End Use
9.3.4. Egypt PD-L1 Biomarker Testing Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Cancer Type
9.3.4.2.2. By Assay Kit Type
9.3.4.2.3. By End Use
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global PD-L1 Biomarker Testing Market: SWOT Analysis
13. Porter?s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. Competitive Landscape
14.1. AstraZeneca PLC
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Current Capacity Analysis
14.1.5. Financials (In case of listed)
14.1.6. Recent Developments
14.1.7. SWOT Analysis
14.2. Merck Group (SigmaAldrich Co., LLC)
14.3. F. Hoffmann-La Roche Ltd.
14.4. Abcam
14.5. Agilent technologies
14.6. NeoGenomics Laboratories, Inc.
14.7. ACROBiosystems
14.8. PerkinElmer Inc.
14.9. Guardant Health
14.10. Quanterix
15. Strategic Recommendations
16. About Us & Disclaimer